Research Article

Inhibitory Effect on Cerebral Inflammatory Response following Traumatic Brain Injury in Rats: A Potential Neuroprotective Mechanism of N-Acetylcysteine

Gang Chen, Jixin Shi, Zhigang Hu, and Chunhua Hang

Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Nanjing, Jiangsu 210002, China

Correspondence should be addressed to Chunhua Hang, nju_neurosurgery@163.com

Received 17 December 2007; Accepted 28 March 2008

Although N-acetylcysteine (NAC) has been shown to be neuroprotective for traumatic brain injury (TBI), the mechanisms for this beneficial effect are still poorly understood. Cerebral inflammation plays an important role in the pathogenesis of secondary brain injury after TBI. However, it has not been investigated whether NAC modulates TBI-induced cerebral inflammatory response. In this work, we investigated the effect of NAC administration on cortical expressions of nuclear factor kappa B (NF-κB) and inflammatory proteins such as interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1) after TBI. As a result, we found that NF-κB, proinflammatory cytokines, and ICAM-1 were increased in all injured animals. In animals given NAC post-TBI, NF-κB, IL-1β, TNF-α, and ICAM-1 were decreased in comparison to vehicle-treated animals. Measures of IL-6 showed no change after NAC treatment. NAC administration reduced brain edema, BBB permeability, and apoptotic index in the injured brain. The results suggest that post-TBI NAC administration may attenuate inflammatory response in the injured rat brain, and this may be one mechanism by which NAC ameliorates secondary brain damage following TBI.

Copyright © 2008 Gang Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Although traumatic brain injury (TBI) represents a significant public health problem in the world, there are currently no treatments that improve clinical outcome measures [1, 2]. Recently, several reports from experimental studies have demonstrated that N-acetylcysteine (NAC) played neuroprotective roles in TBI including restoration of TBI-induced mitochondrial dysfunction, increasing the reduced antioxidant enzyme, and protecting neurons [3–5]. Most of these previous studies focused on the modulation of NAC on oxidative stress in the brain following TBI, but ignored the influence of NAC on cerebral inflammation, which also played crucial roles in the mechanisms of secondary brain damage after TBI [6]. Furthermore, no study was found in the literature to investigate the effects of NAC administration on brain edema, blood-brain barrier (BBB) permeability, and cortical apoptosis following TBI.

Several clinical and experimental studies have demonstrated that secondary brain injury can be magnified by numerous immune mediators, which are frequently upregulated in response to TBI [7–9]. Increased levels of these molecules within the injured brain, including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1), are believed to contribute to the cerebral damage, cell death, and BBB dysfunction [10]. A pivotal player in the regulation of these molecules is the nuclear factor kappa B (NF-κB) family (cRel, RelA/p65, RelB, p50 and p52) of transcription factors [11, 12]. In our previous studies, we have demonstrated that cortical contusion trauma could induce a concomitant and persistent upregulation of NF-κB, TNF-α, IL-6, and ICAM-1 in the injured rat brain, which might play a central role in the injury-induced inflammatory response of brain [13, 14].

NAC is a compound that increases the pool of glutathione. The latter is an important cellular antioxidant.
It is a reactive oxygen species (ROS) scavenger and can restore the reduced cellular glutathione [15]. It is also cytoprotective since it inhibits the activation of NF-κB and TNF-α production by lipopolysaccharide [16, 17]. Xiong et al. have reported that NAC could greatly restore brain glutathione levels and mitochondrial glutathione levels after TBI [3]. Also, in a rat model of experimental stroke, administration of NAC after ischemia onset protected the brain from free radical injury, apoptosis, and inflammation, with a wide treatment window [18]. Nevertheless, it is still unknown up till now whether NAC can affect the production of inflammatory agents in the brain after TBI.

The aim of the current study was to determine whether NAC could attenuate the TBI-induced brain inflammation in the pericontusional area. We hypothesized that the effect of NAC on modulating cerebral inflammatory response might be a mechanism by which NAC reduced cerebral edema, protected BBB, and repressed cortical apoptosis after TBI.

2. MATERIALS AND METHODS

2.1. Animals

Male Wistar rats (250–300 g) were purchased from Animal Center of Chinese Academy of Sciences, Shanghai, China. The rats were housed in temperature and humidity controlled animal quarters with a 12-hour light/dark cycle. All procedures were approved by the Institutional Animal Care Committee and were in accordance with the guidelines of the National Institutes of Health on the care and use of animals.

2.2. Experiment protocol

Rat model of cortical contusion trauma: following IP anesthesia with urethane (1000 mg/kg), animal head was fixed in the stereotactic frame. A right parietal craniotomy (diameter 5 mm) was drilled under aseptic conditions 1 mm posterior and 2 mm lateral to the bregma. We used a modification of Feeney’s weight-drop model in which a freefalling weight onto the exposed intact cranial dura produced a standardized parietal contusion by letting a steel rod weighing 40 g with a flat end diameter of 4 mm fall onto a piston resting on the dura from a height of 25 cm [19]. The piston was allowed to compress the tissue a maximum of 5 mm. After operation procedures, the rats were then returned to their cages and the room temperature kept at 23 ± 1°C. Heart rate, arterial blood pressure, and rectal temperature were monitored, and the rectal temperature was kept at 37 ± 0.5°C, by using physical cooling (ice bag) when required, throughout experiments. Sham-operated rats were anesthetized and mounted in the stereotactic apparatus, with right parietal craniotomy surgically prepared alone and without brain injury.

We established 3 experimental groups in a randomized fashion: (a) the sham operation group (SHAM; n = 15), (b) the TBI group (TBI; n = 18), and (c) the NAC treatment group (TBI-NAC; n = 18). Rats of TBI-NAC group received injections of 150 mg/kg NAC IP at 15 minutes and 1, 2, and 3 days after the surgery. Rats of SHAM and TBI groups received equal volumes of 0.9% saline solution. The dose was chosen according to Hicdonmez et al. since they observed beneficial effects on preventing trauma-induced oxidative brain tissue damage following TBI after treatment with NAC using the same protocol [4]. The animals were decapitated 3 days after injury for tissue assays. The surrounding brain tissue of the injured cortex (see Figure 1) was dissected on ice as described in our previous study [14], some of which were put into 10% buffered formalin, the others were stored at liquid nitrogen immediately until use.

2.3. Nuclear protein extract and electrophoretic mobility shift assay (EMSA)

Nuclear protein was extracted and quantified as described [14, 20]. EMSA was performed using a commercial kit (Gel Shift Assay System; Promega, Madison, Wis, USA) following the methods in our laboratory. The NF-κB oligonucleotide probe (5′-AGTTGAGGGGACTTTCCCAGGC-3′) was end-labeled with [γ-32P] ATP (Free Biotech, Beijing, China). EMSA was performed according to our previous study [14, 20].

2.4. Enzyme-linked immunosorbent assay (ELISA)

The levels of inflammatory mediators were quantified using specific ELISA kits for rats according to the manufacturers’ instructions (TNF-α from Diaclone Research, Besançon, France; IL-1β, IL-6 from Biosource Europe SA, Nivelles, Belgium) and our previous studies [14, 20]. Values were expressed as ng/g protein.

2.5. Immunohistochemical study

Immunohistochemical studies were conducted on formalin-fixed, paraffin-embedded sections. The rabbit-antirat monoclonal antibody of ICAM-1 (diluted 1:100, Santa Cruz Biotechnology, Calif, USA) was used. Immunohistochemical
assay was performed according to our previous study [14]. The positive cells were identified, counted, and analyzed under the light microscope by an investigator blinded to the grouping. The number of positive microvessels in each section was counted in 10 microscopic fields (at \( \times 100 \) magnifications) and averaged for the positively immunostained vessel number of per visual field.

### 2.6. Brain water content

Brain edema was determined using the wet/dry method as previously described where the percentage of brain water = \([\text{(wet weight} - \text{dry weight})/\text{wet weight}] \times 100\% \) [21]. Briefly, brains were rapidly removed from the skull and the bilateral brains were separated. Both were placed separately into preweighed and labeled glass vials and weighed. The vials were then placed in an oven for 72 hours at 100°C and then reweighed to obtain dry weight content. The number of animals used in each group for brain edema study was as follows: for SHAM \((n = 5)\), for TBI \((n = 6)\), and for TBI-NAC \((n = 6)\).

### 2.7. Blood-brain barrier permeability

Blood-brain barrier (BBB) permeability was determined by Evans blue (EB) extravasation at 3 days after TBI. Briefly, 2% Evans blue was injected IV at a dose of 2 mL/kg. Animals were then reanesthetized after 1 hour with urethane (1000 mg/kg) and perfused using saline to remove intravascular EB dye. Animals were then decapitated; the brains were removed and homogenized in phosphate buffered saline. Trichloroacetic acid was then added to precipitate protein, and the samples were cooled and centrifuged. The resulting supernatant was measured for absorbance of EB at 610 nm using a spectrophotometer. The number of animals used in each group for BBB permeability study was as follows: for SHAM \((n = 5)\), for TBI \((n = 6)\), and for TBI-NAC \((n = 6)\).

### 2.8. TUNEL staining and quantitation of apoptotic cells

The formalin-fixed tissues were embedded in paraffin and sectioned at 4 μm thickness with a microtome. The sections were detected for apoptotic cells by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method. TUNEL: in situ cell death detection kit POD (ISCDD, Boehringer Mannheim, Germany) was used. The procedures were according to the protocol of the kit and our previous study [14]. The positive cells were identified, counted, and analyzed under the light microscope by an investigator blinded to the grouping. The extent of brain damage was evaluated by apoptotic index which was the average number of TUNEL-positive cells in each section counted in 10 microscopic fields (at \( \times 200 \) magnifications).

### 2.9. Statistical analysis

All data were presented as mean ± SD. SPSS 12.0 was used for statistical analysis of the data. All data were subjected to one-way ANOVA. Differences between experimental groups were determined by Fisher’s LSD posttest. Statistical significance was inferred at \( P < .05 \).

### 3. RESULTS

#### 3.1. EMSA for NF-κB

EMSA autoradiography of NF-κB DNA binding activity of the injured brain samples was shown in Figure 2. Low NF-κB binding activity (weak EMSA autoradiography) was found in the SHAM group. Compared with SHAM group, NF-κB binding activity in the injured brain was significantly increased \((P < .01)\) in TBI group. In TBI-NAC group, the NF-κB binding activity was significantly downregulated \((P < .01)\) in the brain area surrounding the injury site after TBI.

#### 3.2. Concentrations of IL-1β, TNF-α, and IL-6 in the injured brains

Concentrations of IL-1β, TNF-α, and IL-6 were low in the rat brains of SHAM group \((6.16 \pm 1.63, 0.58 \pm 0.20, \text{and } 0.19 \pm 0.03 \text{ng/g protein, resp.})\) (see Figure 3). Compared with SHAM group, cortical levels of the three inflammatory cytokines were greatly induced after TBI \((P < .01)\). As shown in Figure 3, NAC administration after TBI could lead to
significant decrease in brain water content had no significant difference among SHAM, TBI, and TBI-NAC groups. The results suggested that post-TBI NAC treatment could attenuate brain edema in this rat TBI model.

3.5. Blood-brain barrier permeability

The pattern of Evans blue extravasation following TBI is shown in Figure 6. Rats in TBI group demonstrated a significant increase (P < .01) in BBB permeability to Evans blue relative to rats of SHAM group. Administration of NAC significantly inhibited Evans blue extravasation (P < .05), indicating a reduced BBB opening in response to NAC treatment.

3.6. Apoptosis in the injured cortex

Few TUNEL-positive apoptotic cells were found in the SHAM group rat brain (see Figure 7(a)). In TBI group, the apoptotic index in the cortex surrounding the injured site was found to be significantly increased compared with that in SHAM animals (P < .01) (see Figures 7(b) and 7(d)). In TBI-NAC group, when compared with that in the TBI group, the apoptotic index in the studied cortex was significantly decreased (P < .01) (see Figures 7(c) and 7(d)). The result showed that NAC administration following TBI could lead less cell death in the brain surrounding the cortical contusion and was potential to ameliorate the secondary brain damage following TBI.

4. DISCUSSION

The main findings of this study are that (1) as common inflammation-related factors to TBI, NF-κB, proinflammatory cytokines, and ICAM-1 were upregulated after TBI and could be suppressed when treated with NAC and (2) after NAC administration, the brain edema, BBB permeability, and apoptotic cell death were ameliorated. These findings suggest for the first time that NAC attenuates the TBI-induced cerebral inflammatory response and alleviates secondary brain damage following primary trauma in the rat TBI model.

There have been several studies focusing on the neuroprotective effects of NAC in TBI. As mentioned by Ellis et al. in their literature, NAC could direct scavenge radicals and stimulate glutathione peroxidase activity in a cat TBI model [22]. Their results suggested that NAC might be useful for treatment of oxygen-free radical-mediated brain injury. Another research indicated that NAC administered postinjury at an early stage could effectively restore TBI-induced mitochondrial dysfunction and the protective effect of NAC might be related to its restoration of glutathione levels in the brain [3]. More recent data revealed by Hicdonmez et al. was that NAC treatment after trauma was effective in lipid peroxidation, antioxidant enzyme activity, and neuronal protection in cerebral injury following closed head trauma [4]. In this current study, we found that NAC administration following TBI could reduce cerebral edema, BBB permeability, and apoptotic cell death which
played important roles and were the major part in the secondary brain injury following TBI. However, despite the demonstrated mechanisms of NAC in neuroprotection, none of the previous studies focused on cerebral inflammatory response that might facilitate the development of secondary brain damage following primary trauma.

Brain inflammation represents only one of the numerous processes activated after TBI; it has not been fully elucidated due to the complexity of the large number of molecules shaping a sophisticated circuitry. The major effectors in this cascade are the proinflammatory cytokines that are...
Mediators of Inflammation

usually released within minutes after challenge because they are stored intracellularly as precursor proteins eventually modified into active molecules. TBI damages the blood-brain barrier, then the blood cells such as neutrophils and macrophages accumulate in the brain and further sustain the cerebral inflammatory cascade [23]. Numerous immune mediators such as IL-1β, TNF-α, and IL-6 released within minutes of the primary injury can initiate the infiltration of inflammatory cells into the brain by activating ICAM-1 and other adhesion molecules [14]. The functional importance of NF-κB in acute inflammation is based on its ability to regulate the promoters of a variety of genes whose products, such as IL-1β, TNF-α, IL-6, and acute phase proteins, are critical to inflammatory processes [11]. NF-κB activation enhances the transcription of proinflammatory cytokines, and the cytokines are known to in turn activate NF-κB [24]. The positive feedback is believed to serve to amplify inflammatory signals. In our previous studies, it has been found that there were an early concomitant and persistent upregulation of NF-κB binding activity, TNF-α, IL-6, and ICAM-1 expression in the injured brain after cortical contusion trauma [13, 14].

A number of studies have demonstrated that NAC could modulate inflammatory factors production such as NF-κB, proinflammatory cytokines, and ICAM-1 [25]. Carroll et al. examined the influence of NAC on cerebral NF-κB activity after temporary middle cerebral artery occlusion and indicated that activated NF-κB was significantly increased 15 minutes after reperfusion in the affected hemisphere and could be abolished with NAC treatment [25]. Li et al. investigated effects of NAC on NF-κB activation and proinflammatory cytokines production in protein malnutrition using an animal septic shock model and their results suggested that supplementation of NAC could normalize lipopolysaccharide-induced NF-κB activation and proinflammatory cytokines production during early rehabilitation of protein malnourished mice [26]. Our study showed that cortical levels of NF-κB, TNF-α, IL-1β, IL-6, and ICAM-1 were significantly induced by TBI at 3 days after trauma. Post-TBI NAC administration could repress the expressions of most of these inflammatory agents that accompanied TBI. Although our data have proved that NAC could downregulate the cerebral inflammatory factors after TBI, changes about the signaling pathways of inflammation and oxidative

Figure 7: TUNEL immunohistochemistry staining of the injured cortex in SHAM group (n = 5), TBI group (n = 6), and TBI-NAC group (n = 6). (a) SHAM group rats showing few TUNEL apoptotic cells. (b) TBI group rats showing more TUNEL apoptotic cells stained as brown. (c) TBI-NAC group rats showing less TUNEL apoptotic cells than TBI group (scar bar, 50 μm). (d) Administration of NAC significantly decreased the apoptotic index in rat injured brain following TBI. **P < .01 versus SHAM group; ##P < .01 versus TBI group.
stress in the brain remain unknown. It is assured that further ingenious studies are needed and will be conducted in our laboratory.

Apoptosis in the traumatically injured brain occurs not only at the impact site but also as a result of secondary brain insults such as intracranial hypertension, hypoxia, or disturbances of microcirculation [27]. Studies regarding the effect of NAC on neural apoptosis after TBI have not been found to date. Nevertheless, several previous studies have demonstrated that NAC could prevent apoptotic death of neuronal cells in vitro [28, 29]. NAC also inhibited procaspase-9 processing and the activation of enzymatic activity of caspasases induced by acrolein. Inhibition of acrolein-induced apoptosis using NAC was confirmed morphologically by diminished condensation of nuclear chromatin, as evaluated by fluorescence microscopy [30]. In this present study, we found that systemic NAC administration could inhibit apoptotic cell death in the injured brain and was potential to reduce the secondary brain damage following TBI. However, it is still unclear whether NAC can modulate the apoptotic signals and the whole mechanisms involved call for further research.

In conclusion, to the best of our knowledge, this is the first study to demonstrate the effect of NAC on the inflammatory response in the injured brain after TBI. We found that TBI could upregulate the expressions of NF-κB, IL-1β, TNF-α, and ICAM-1 in the surrounding brain of injured site, which could be markedly inhibited by NAC administration. The therapeutic benefit of post-TBI NAC administration might be due to its salutary effect on modulating cerebral inflammation secondary to TBI.

ACKNOWLEDGMENTS

The authors thank Dr. Bo Wu and Dr. Geng-bao Feng for their technical assistance. This work was partially supported by grants from the China Scholarship Council (CSC).

REFERENCES

[1] I. Roberts, G. Schierhout, and P. Alderson, “Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: a systematic review,” *Journal of Neurology Neurosurgery and Psychiatry*, vol. 65, no. 5, pp. 729–733, 1998.

[2] J. A. McKee, R. P. Brewer, G. E. Macy, C. O. Borel, J. D. Reynolds, and D. S. Warner, “Magnesium neuroprotection is limited in humans with acute brain injury,” *Neurocritical Care*, vol. 2, no. 3, pp. 342–351, 2005.

[3] Y. Xiong, P. L. Peterson, and C. P. Lee, “Effect of N-acetylcysteine on mitochondrial function following traumatic brain injury in rats,” *Journal of Neurotrauma*, vol. 16, no. 11, pp. 1067–1082, 1999.

[4] T. Hicdondmez, M. Kanter, M. Tiryaki, T. Parsak, and S. Cobanoglu, “Neuroprotective effects of N-acetylcysteine on experimental closed head trauma in rats,” *Neurochemical Research*, vol. 31, no. 4, pp. 473–481, 2006.

[5] J.-H. Yi, R. Hoover, T. K. McIntosh, and A. S. Hazell, “Early, transient increase in complex I and complex II in the cerebral cortex following traumatic brain injury is attenuated by N-acetylcysteine,” *Journal of Neurotrauma*, vol. 23, no. 1, pp. 86–96, 2006.

[6] M. C. Morganti-Kossmann, M. Rancan, V. I. Otto, P. F. Stahel, and T. Kossmann, “Role of cerebral inflammation after traumatic brain injury: a revisited concept,” *Shock*, vol. 16, no. 3, pp. 165–177, 2001.

[7] S. M. Knoblach, L. Fan, and A. I. Faden, “Early neuronal expression of tumor necrosis factor-α after experimental brain injury contributes to neurological impairment,” *Journal of Neuroimmunology*, vol. 95, no. 1-2, pp. 115–125, 1999.

[8] V. H. J. Hans, T. Kossmann, P. M. Lenzlinger, et al., “Experimental axonal injury triggers interleukin-6 mRNA, protein synthesis and release into cerebrospinal fluid,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 19, no. 2, pp. 184–194, 1999.

[9] M. Rancan, V. I. Otto, V. H. J. Hans, et al., “Upregulation of ICAM-1 and MCP-1 but not of MIP-2 and sensorimotor deficit in response to traumatic axonal injury in rats,” *Journal of Neuroscience Research*, vol. 63, no. 5, pp. 438–446, 2001.

[10] J. E. Merrill and E. N. Benveniste, “Cytokines in inflammatory brain lesions: helpful and harmful,” *Trends in Neurosciences*, vol. 19, no. 8, pp. 331–338, 1996.

[11] P. A. Baeuerle and D. Baltimore, “NF-κB: ten years after,” *Cell*, vol. 87, no. 1, pp. 13–20, 1996.

[12] M. Grilli and M. Memo, “ Nuclear factor-xB/Rel proteins: a point of convergence of signaling pathways relevant in neuronal function and dysfunction,” *Biochemical Pharmacology*, vol. 57, no. 1, pp. 1–7, 1999.

[13] C. Hang, G. Chen, J. Shi, X. Zhang, and J. S. Li, “Cortical expression of nuclear factor xB after human brain contusion,” *Brain Research*, vol. 1109, no. 1, pp. 14–21, 2006.

[14] C. Hang, J. Shi, J. Tian, J. S. Li, W. Hu, and H. X. Yin, “Effect of systemic LPS injection on cortical NF-κB activity and inflammatory response following traumatic brain injury in rats,” *Brain Research*, vol. 1026, no. 1, pp. 23–32, 2004.

[15] T. Akca, H. Canbaz, C. Tataroglu, et al., “The effect of N-acetylcysteine on pulmonary lipid peroxidation and tissue damage,” *Journal of Surgical Research*, vol. 129, no. 1, pp. 38–45, 2005.

[16] B.-G. Hsu, R.-P. Lee, F.-L. Yang, H.-J. Harn, and H. I. Chen, “Post-treatment with N-acetylcysteine ameliorates endotoxin shock-induced organ damage in conscious rats,” *Life Sciences*, vol. 79, no. 21, pp. 2010–2016, 2006.

[17] E. Hofer, Y. Baum, and M. A. Nahir, “N-acetylcysteine enhances the action of anti-inflammatory drugs as suppressors of prostaglandin production in monocytes,” *Mediators of Inflammation*, vol. 11, no. 5, pp. 321–323, 2002.

[18] M. Khan, B. Sekhon, M. Jatana, et al., “Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke,” *Journal of Neuroscience Research*, vol. 76, no. 4, pp. 519–527, 2004.

[19] D. M. Feeney, M. G. Boyeson, R. T. Linn, H. M. Murraya, and W. G. Dail, “Responses to cortical injury—II: methodology and local effects of contusions in the rat,” *Brain Research*, vol. 211, no. 1, pp. 67–77, 1981.

[20] G. Chen, J. Shi, Y. Ding, H. Yin, and C. Hang, “Progesterone prevents traumatic brain injury-induced intestinal nuclear factor kappa B activation and proinflammatory cytokines expression in male rats,” *Mediators of Inflammation*, vol. 2007, Article ID 93431, 7 pages, 2007.
[21] R. Vink, A. Young, C. J. Bennett, et al., “Neuropeptide release influences brain edema formation after diffuse traumatic brain injury,” Acta Neurochirurgica. Supplement, vol. 86, pp. 257–260, 2003.

[22] E. F. Ellis, L. Y. Dodson, and R. J. Police, “Restoration of cerebrovascular responsiveness to hyperventilation by the oxygen radical scavenger N-acetylcysteine following experimental traumatic brain injury,” Journal of Neurosurgery, vol. 75, no. 5, pp. 774–779, 1991.

[23] T. M. Carlos, R. S. B. Clark, D. Franicola-Higgins, J. K. Schiding, and P. M. Kochanek, “Expression of endothelial adhesion molecules and recruitment of neutrophils after traumatic brain injury in rats,” Journal of Leukocyte Biology, vol. 61, no. 3, pp. 279–285, 1997.

[24] M. F. Neurath, S. Pettersson, K.-H. Meyer zum B¨uschenfelde, and W. Strober, “Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice,” Nature Medicine, vol. 2, no. 9, pp. 998–1004, 1996.

[25] J. E. Carroll, E. F. Howard, D. C. Hess, C. G. Wakade, Q. Chen, and C. Cheng, “Nuclear factor-κB activation during cerebral reperfusion: effect of attenuation with N-acetylcysteine treatment,” Molecular Brain Research, vol. 56, no. 1-2, pp. 186–191, 1998.

[26] J. Li, N. Quan, and T. M. Bray, “Supplementation of N-acetylcysteine normalizes lipopolysaccharide-induced nuclear factor κB activation and proinflammatory cytokine production during early rehabilitation of protein malnourished mice,” Journal of Nutrition, vol. 132, no. 11, pp. 3286–3292, 2002.

[27] A. C. Conti, R. Raghupathi, J. Q. Trojanowski, and T. K. McIntosh, “Experimental brain injury induces regionally distinct apoptosis during the acute and delayed post-traumatic period,” Journal of Neuroscience, vol. 18, no. 15, pp. 5663–5672, 1998.

[28] A. K. Talley, S. Dewhurst, S. W. Perry, et al., “Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA,” Molecular and Cellular Biology, vol. 15, no. 5, pp. 2359–2366, 1995.

[29] G. Ferrari, C. Y. Yan, and L. A. Greene, “N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells,” Journal of Neuroscience, vol. 15, no. 4, pp. 2857–2866, 1995.

[30] A. Tanel and D. A. Averill-Bates, “Inhibition of acrolein-induced apoptosis by the antioxidant N-acetylcysteine,” Journal of Pharmacology and Experimental Therapeutics, vol. 321, no. 1, pp. 73–83, 2007.